Comment from Alzheimer's Association
AnonymousSupportAdvocacy
Summary: The Alzheimer's Association and the Alzheimer's Impact Movement support the FDA's exploration of drug repurposing to address unmet medical needs in Alzheimer's disease. They advocate for creating financial incentives, improving interagency data sharing (specifically with NIA, AHRQ, and CMS), and integrating real-world evidence like Medicare/Medicaid claims and ADNI data into the FDA's signal-detection infrastructure.
The Alzheimer's Association and the Alzheimer's Impact Movement appreciate the opportunity to submit the attached responses to the Food and Drug Administration's Request for Information on Drug Repurposing for Unmet Medical Needs. Please do not hesitate to contact us with additional questions or if we can be of assistance.
Thank you,
Laura Thornhill